Levodopa/Carbidopa (Hengrui Medicine)

左旋多巴/卡比多巴（恒瑞医药）

Report date: 2025/01/15 13:14:41

Base Information

Drug NameLevodopa/Carbidopa (Hengrui Medicine)
Drug Alias NameCarbidopa/levodopa (Hengrui Medicine)HRG-2010
ClassificationSmall molecules
Mechanisms of ActionDopamine receptors agonistsDOPA decarboxylase inhibitors
TargetsDopamine receptorsAromatic-L-amino-acid decarboxylase
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A